Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
NEW YORK, April 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDEV, CMRX, TXMD, PEI, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sel…
Q1 2020 TherapeuticsMD Inc Earnings Call
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 26) * Aptevo Therapeutics Inc (NASDAQ: APVO) (reacted to its fourth-quarter results) * TFF Pharmaceuticals Inc (NASDAQ: TFFP)Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Stocks In Focus Sanofi's Multiple Myeloma Drug Gets Positive European Regulatory Agency Committee Opinion Sanofi SA (NASDAQ: SNY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.In premarket trading Friday, the stock was up 1.28% to $43.50.Translate Bio, Sanofi to Partner for COVID-19 Vaccine Research Translate Bio Inc (NASDAQ: TBIO) Bio said it will collaborate with Sanofi to develop a mRNA vaccine for COVID-19, joining a host of companies working on a vaccine for the SARS-CoV-2. Translate Bio has begun to produce multiple mRNA constructs, and it expects to use its mRNA platform for developing SARS-CoV-2 vaccine candidate.Separately, Translate Bio said the FDA has granted Rare Pediatric Disease designation for MRT5005 for the treatment of cystic fibrosis, its first inhaled mRNA therapeutic. The company also said it expects interruptions in enrolment, dosing and follow-up in the ongoing Phase 1/2 trial in patients with cystic fibrosis.It said it will provide an updated timing on the interim data readout of the additional single-ascending dose group and the multiple ascending dose portion of the trial at a later date.Translate Bio shares were jumping 21.95% to $12.50 in premarket trading Friday.TherapeuticsMD Suspends FY20 Guidance, Announces Cost Cuts TherapeuticsMD Inc (NASDAQ: TXMD) pre-announced first-quarter total net revenues of more than $11 million, while analysts expect revenues of $11.64 million. The company said it is suspending its 2020 guidance, citing the unknown impact of COVID-19 on its business.The company also announced measures to cut or defer more than $30 million in annual spending.The stock was slipping 7.75% to $1.19 in premarket trading Friday.Zealand Announces Private Placement of Common Stock Danish biotech ZEALAND PHARMA/S ADR (NASDAQ: ZEAL) announced a private placement and directed share issue of 741,816 new ordinary shares to a U.S.-based investor at 185 Danish Krone per new ordinary share. The company said it expects to receive gross proceeds from the placement of about 137,236,000 Danish Krone.The company said it will use the net proceeds for supporting its peptide platform, accelerating development of late stage assets, and prepare for the launch of its first fully-owned asset.Arbutus Announces Positive Early-stage Results For Hepatitis B Drug Arbutus Biopharma Corp (NASDAQ: ABUS) announced positive preliminary results from a Phase 1a/1b clinical study of its RNAi therapy AB-729 in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy. The study was meant to determine the most effective dose and dosing interval for use in future Phase 2 combination clinical trials.View more earnings on IBB"These encouraging preliminary results demonstrate that AB-729 is a potent RNAi agent capable of reducing HBsAg plasma levels and support its further development as a treatment for people living with chronic hepatitis B," the company said.The stock was advancing 3.98% to $2.35 in premarket trading Friday.Earnings Neubase Therapeutics Inc's (NASDAQ: NBSE) fourth quarter net loss widened from 25 cents in 2018 to 26 cents in 2019, but was narrower than the consensus loss estimate of 32 cents per share. The company said its current cash balance will provide sufficient capital to fund operations through the end of fiscal year 2020.In premarket trading Friday, Neubase shares were rallying 19.28% to $6.99.NovaBay Pharmaceuticals, Inc.'s (NYSE: NBY) fourth-quarter revenues fell from $3.6 million in 2018 to $1.7 million in 2019. The net loss per share widened from 7 cents to 13 cents. Analysts had estimated a loss of 7 cents per share.The stock was plunging 10.92% to 78 cents in premarket trading Friday.aTyr Pharma Inc (NASDAQ: LIFE) reported total revenues of $0.1 million and a loss of $1.54 per share for the fourth quarter of 2019. In the year-ago quarter, the company reported no revenues and a loss of $2.92 per share. The consensus estimate had called for a loss of $1.59 per share for the recent fourth quarter.As of Dec. 31, the company had cash, cash equivalents and investments of about $31.1 million.In premarket trading, the shares were adding 5.84% to $3.26.Vir Biotechnology Inc (NASDAQ: VIR), which is working on a cure for the new coronavirus, reported a decline in its fourth-quarter revenues from $3.1 million in 2018 to $1 million in 2019. The net loss per share widened from $3.05 to 71 cents, while analysts estimated a loss of 67 cents per share for the quarter.The stock was advancing 5% to $33.60 in premarket trading.On The Radar Earnings TELA Bio Inc (NASDAQ: TELA) (before the market open) Zyla Life Sciences (OTC: ZCOR) (before the market open) Ocugen Inc (NASDAQ: OCGN) (before the market open) Altimmune Inc (NASDAQ: ALT) (before the market open)See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger * The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down * Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
TXMD releases financial and business results for Q1 2020; Q1 revenue exceeded Wall Street consensus; conference call scheduled for today at 8:30 a.m.
My worst fear was realized with the poor sales trajectory, challenging payor coverage and a total shift in business strategy.COVID-19 situation has further exacerbated the problem resulting in the suspension of "conservative" guidance.Even under an optimistic…
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases financial and business results for Q1 2020; Q1 revenue exceeded Wall Street consensus; conference call scheduled for today at 8:30 a.m.
Q1 2020 TherapeuticsMD Inc Earnings Call
TXMD's CEO to present at BofA Securities 2020 Health Care Conference to be held virtually on May 13 at 9:40 a.m. ET
NEW YORK, April 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDEV, CMRX, TXMD, PEI, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sel…
TherapeuticsMD, Inc. (NASDAQ:TXMD) just released its latest annual results and things are looking bullish. The overall...
Shares of TherapeuticsMD (NASDAQ:TXMD) rose 7.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share fell 31.25% over the past year to ($0.21), which missed the estimate of ($0.19).Revenue of $12,251,000 higher by 210.39% from the same period last year, which beat the estimate of $11,300,000.Looking Ahead TherapeuticsMD hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 06, 2020View more earnings on TXMDWebcast URL: https://edge.media-server.com/mmc/p/ms587etoPrice Action 52-week high: $4.69Company's 52-week low was at $0.85Price action over last quarter: down 27.67%Company Description TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.See more from Benzinga * 16 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
TXMD provides business update on COVID-19
The United States Patent and Trademark Office has issued TherapeuticsMD a label patent for Annovera, a prescription hormonal birth control treatment for women developed by the Boca Raton-based company (Nasdaq: TXMD). TherapeuticsMD has 30 days to submit the …
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to hold conference call on May 6 @ 8:30 a.m. ET to discuss Q1 2020 financial and business results.
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointments of Paul Bisaro and Gail Naughton, Ph.D., to the Company’s Board of Directors. The appointments fill two of the vacancies created by the resignations from the Board of Brian Bernick, M.D., John C.K. Milligan, IV and Nicholas Segal. Dr. Bernick will continue to serve as a Co-Founder of TherapeuticsMD on a full-time basis, supporting the Company’s outreach with healthcare providers. Mr. Milligan will continue to serve as the President of TherapeuticsMD on a full-time basis, leading the Company’s infrastructure and critical operations.
TXMD to hold conference call on May 6 @ 8:30 a.m. ET to discuss Q1 2020 financial and business results.
A newly issued patent could provide market exclusivity for its long-term contraceptive device.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD obtains patent protection for ANNOVERA into 2039
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointment of Karen L. Ling to the Company’s Board of Directors.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD's CEO to present at BofA Securities 2020 Health Care Conference to be held virtually on May 13 at 9:40 a.m. ET
Q1 2020 TherapeuticsMD Inc Earnings Call
Q4 2019 TherapeuticsMD Inc Earnings Call
Thank you for joining us for the TherapeuticsMD First Quarter 2020 Financial Results Conference Call. This morning, TherapeuticsMD issued a press release announcing our first quarter financial results. On today's call from TherapeuticsMD are Chief Executive Officer, Robert Finizio; Chief Commercial Officer, Dawn Halkuff; and Mitchell Krassan, our Chief Strategy and Performance Officer.
TXMD earnings call for the period ending March 31, 2020.
The United States Patent and Trademark Office has issued TherapeuticsMD a label patent for Annovera, a prescription hormonal birth control treatment for women developed by the Boca Raton-based company (Nasdaq: TXMD). TherapeuticsMD has 30 days to submit the …
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD releases COVID-19 business update with contingency plan to be implemented in Q2 and Q3; Q1 revenue expected at more than $11 million
TXMD obtains patent protection for ANNOVERA into 2039
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.